Acurx Pharmaceuticals (NASDAQ:ACXP) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Acurx Pharmaceuticals (NASDAQ:ACXP) announced its quarterly earnings results on Monday. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.02, Zacks reports.

Acurx Pharmaceuticals Trading Up 3.3 %

NASDAQ ACXP opened at $0.42 on Wednesday. The firm has a market cap of $8.22 million, a price-to-earnings ratio of -0.38 and a beta of -1.71. The company has a 50 day moving average of $0.71 and a 200-day moving average of $1.27. Acurx Pharmaceuticals has a 1-year low of $0.40 and a 1-year high of $3.33.

Insider Transactions at Acurx Pharmaceuticals

In related news, CEO David P. Luci purchased 49,261 shares of the stock in a transaction that occurred on Monday, January 6th. The stock was acquired at an average price of $1.01 per share, with a total value of $49,753.61. Following the completion of the acquisition, the chief executive officer now directly owns 1,097,458 shares in the company, valued at approximately $1,108,432.58. This trade represents a 4.70 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 29.60% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $12.00 price objective on shares of Acurx Pharmaceuticals in a report on Friday, January 10th.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.